Immuron, an Australian biopharmaceutical company (ASX:IMC), saw its shares climb high as much as 13.3% to A$0.085, marking the biggest intraday percentage gain since September 13.

Immuron (ASX:IMC) experienced its highest level since the same day in September.

The boost followed record Q1 sales of the firm’s digestive health immune supplement, Travelan, which amounted to A$1.3 million, compared to A$25,565 in Q1 of FY23.

Immuron (ASX:IMC) expects further demand for Travelan’s resupply as retail pharmacies continue to sell the product to consumers.

Nearly 189,200 company (ASX:IMC) shares exchanged hands by 0253 GMT, compared to the 30-day average volume of 59,912.

Though the shares experienced a decrease of 12.8% year-to-date as of the last closing, this recent increase marks a substantial turnaround.

Immuron (ASX:IMC) concentrates on developing and commercializing oral immunoglobulin treatments for inflammation-mediated and infectious diseases.